Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

Gck Inhibition Is a Novel Therapeutic Strategy for RAS Mutated Multiple Myeloma and Overcomes Resistance to IMiDs

Shirong Li, Jing Fu, PhD, Jun Yang, MS, Markus Y Mapara, MD PhD, Christophe Marcireau, Suzanne Lentzsch, MD PhD

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-143418

Published: 2020

Journal Articles

Resolution of Serious Vaso-Occlusive Pain Crises and Reduction in Patient-Reported Pain Intensity: Results from the Ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy

Alexis A. Thompson, MD, Mark C. Walters, MD, Markus Y Mapara, MD PhD, Janet L. Kwiatkowski, MD MSCE, Lakshmanan Krishnamurti, MD, Banu Aygun, MD, Kimberly A. Kasow, DO, Stacey Rifkin-Zenenberg, DO, Manfred Schmidt, PhD, Jay DelCarpini, Francis J. Pierciey, Jr., Alexandra L. Miller, Meghan E. Gallagher, MSc, Ren Chen, Sunita Goyal, MD, Julie Kanter, MD, John F. Tisdale, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-134940

Published: 2020

Journal Articles

Checkpoint Inhibitor PD-1H/VISTA Mediates MMP-13 Induced Osteoclast Activation and Multiple Myeloma Bone Disease

Jing Fu, PhD, Shirong Li, Huihui Ma, MD PhD, Jun Yang, MS, Gabriel M. Pagnotti, PhD, Stephen J. Weiss, MD PhD, Markus Y Mapara, MD PhD, Suzanne Lentzsch, MD PhD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-142528

Published: 2020

Journal Articles

Glucagon-like Peptide-2 (GLP-2) Treatment Reduces Gvhd-Related Mortality in a Pre-Clinical Transplant Model Via Expansion of Macrophages with Tolerogenic Potential

David W Harle, BBiomedSc, Rodney J Macedo Gonzales, MD PhD, Felix D Rozenberg, BSc, Alexandra Matschiner, Rajat Bansal, MD, Stephen M Lagana, MD, Huihui Ma, MD PhD, Elisha Pinker, Kirubel S Belay, BSc, Ximi K Wang, BSc, Tiffany Thomas, PhD, Markus Y Mapara, MD PhD, Anne-Catrin Uhlemann, MD, Yi Zhang, MD PhD, Ran Reshef, MDMSc

Blood (2020) 136 (Supplement 1): 26–28.

https://doi.org/10.1182/blood-2020-143105

Published: 2020

Journal Articles

Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-139575

Published: 2020

Journal Articles

Improvements in Health-Related Quality of Life for Patients Treated with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy

Julie Kanter, MD, John F. Tisdale, MD, Markus Y Mapara, MD PhD, Janet L. Kwiatkowski, MD MSCE, Lakshmanan Krishnamurti, MD, Ren Chen, Meghan E. Gallagher, MSc, Yuchen Ding, PhD, Sunita Goyal, MD, Clark Paramore, MPH, Alexis A. Thompson, MD, Mark C. Walters, MD

Blood (2020) 136 (Supplement 1): 10.

https://doi.org/10.1182/blood-2020-136193

Published: 2020

Journal Articles

Gck Kinase Activity Is Critical for RAS Mutated Myeloma - a Potential Treatment Approach for Targeting Specific Mutations

Shirong Li, PhD, Jing Fu, PhD, Xiaoming Xu, PhD, Shixian Deng, PhD, Markus Y Mapara, MD PhD, Christophe Marcireau, Suzanne Lentzsch, MD PhD

Blood (2019) 134 (Supplement_1): 1813.

https://doi.org/10.1182/blood-2019-129531

Published: 2019

Journal Articles

Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy

Mark C. Walters, MD, John F. Tisdale, MD, Janet L. Kwiatkowski, MD MSCE, Lakshmanan Krishnamurti, MD, Markus Y. Mapara, MD PhD, Manfred Schmidt, PhD, Alexandra L. Miller, Francis J. Pierciey, Jr., Wenmei Huang, PhD MS, Jean-Antoine Ribeil, MD PhD, Julie Kanter, MD, Alexis A. Thompson, MD MPH

Blood (2019) 134 (Supplement_1): 2061.

https://doi.org/10.1182/blood-2019-128814

Published: 2019

Journal Articles

Excellent Survival and Immune Reconstitution Following Matched/Mismatched Unrelated and Mismatched Related Transplantation in Adult Patients with Sickle Cell Disease: Updated Results from a Single Center Experience

Amer Assal, MD, Diane George, MD, Monica Bhatia, MD, Divaya Bhutani, MD, Christian Gordillo, BS, Suzanne Lentzsch, MD PhD, Ran Reshef, MDMSc, Markus Y Mapara, MD PhD

Blood (2019) 134 (Supplement_1): 2043.

https://doi.org/10.1182/blood-2019-132113

Published: 2019

Journal Articles

Role of MMP-13 in Graft-Versus-Host Disease

Hui-Hui Ma, PhD, Jing Fu, PhD, Suzanne Lentzsch, MD PhD, Markus Y Mapara, MD PhD

Blood (2019) 134 (Supplement_1): 1928.

https://doi.org/10.1182/blood-2019-127703

Published: 2019

Journal Articles

Autologous Transplant Recipients Have a Healthier Gut Microbiota at Baseline and Faster Recovery from Microbiome Injury Compared to Allogeneic Transplant Recipients

Rajat Bansal, MD, Heekuk Park, Cristian Taborda, Christian Gordillo, BS, Markus Y. Mapara, MD PhD, Amer Assal, MD, Anne-Catrin Uhlemann, MD, Ran Reshef, MDMSc

Blood (2019) 134 (Supplement_1): 4491.

https://doi.org/10.1182/blood-2019-129304

Published: 2019

Journal Articles

Checkpoint Inhibitor PD-1H/VISTA Functions As MMP-13 Receptor on Osteoclasts and Mediates MMP-13 Induced Osteoclast Activation in Multiple Myeloma

Jing Fu, PhD, Shirong Li, PhD, Chen Yang, Lewis M Brown, PhD, Stephen J Weiss, MD PhD, Charles G Drake, MD PhD, Markus Y. Mapara, MD PhD, Suzanne Lentzsch, MD PhD

Blood (2019) 134 (Supplement_1): 3072.

https://doi.org/10.1182/blood-2019-129177

Published: 2019

Journal Articles

Resolution of Sickle Cell Disease Manifestations in Patients Treated with Lentiglobin Gene Therapy: Updated Results from the Phase 1/2 Hgb-206 Group C Study

Julie Kanter, MD, John F. Tisdale, MD, Markus Y. Mapara, MD PhD, Janet L. Kwiatkowski, MD MSCE, Lakshmanan Krishnamurti, MD, Manfred Schmidt, PhD, Alexandra L. Miller, Francis J. Pierciey, Jr., Wenmei Huang, PhD MS, Jean-Antoine Ribeil, MD PhD, Alexis A. Thompson, MD MPH, Mark C. Walters, MD

Blood (2019) 134 (Supplement_1): 990.

https://doi.org/10.1182/blood-2019-128894

Published: 2019

Journal Articles

Combination Chemotherapy with Carfilzomib, Bendamustine and Dexamethasone Is Highly Active for Therapy of Newly Diagnosed Multiple Myeloma-Results of Single Center Phase I/II Study

Divaya Bhutani, MD, Siyang Leng, MD, Samuel Pan, Amer Assal, MD, Alexander Wei, Julia Gould, BA, Markus Y. Mapara, MD PhD, Suzanne Lentzsch, MD PhD

Blood (2019) 134 (Supplement_1): 3196.

https://doi.org/10.1182/blood-2019-130207

Published: 2019

Journal Articles

Current Results of Lentiglobin Gene Therapy in Patients with Severe Sickle Cell Disease Treated Under a Refined Protocol in the Phase 1 Hgb-206 Study

John F. Tisdale, MD, Julie Kanter, MD, Markus Y. Mapara, MD PhD, Janet L. Kwiatkowski, MD, Lakshmanan Krishnamurti, MD, Manfred Schmidt, PhD, Alexandra L. Miller, Francis J. Pierciey, Jr., Weiliang Shi, PhD, Jean-Antoine Ribeil, MD PhD, Mohammed Asmal, MD PhD, Alexis A. Thompson, MD MPH, Mark C. Walters, MD

Blood (2018) 132 (Supplement 1): 1026.

https://doi.org/10.1182/blood-2018-99-113480

Published: 2018

Journal Articles

Outcomes for Initial Patient Cohorts with up to 33 Months of Follow-up in the Hgb-206 Phase 1 Trial

Julie Kanter, MD, John F. Tisdale, MD, Janet L. Kwiatkowski, MD, Lakshmanan Krishnamurti, MD, Markus Y. Mapara, MD PhD, Manfred Schmidt, PhD, Alexandra L. Miller, Francis J. Pierciey, Jr., Weiliang Shi, PhD, Jean-Antoine Ribeil, MD PhD, Mark C. Walters, MD, Alexis A. Thompson, MD MPH

Blood (2018) 132 (Supplement 1): 1080.

https://doi.org/10.1182/blood-2018-99-113477

Published: 2018

Journal Articles

Curative Allogeneic Stem Cell Transplantation Is Safe and Feasible in Adult Patients with Sickle Cell Disease Despite Lack of Matched Sibling Donor and Presence of Sickle Cell-Related Co-Morbidities

Amer Assal, MD, Diane George, MD, Monica Bhatia, MD, Christian Gordillo, BS, Nicole Howard, BS, Ran Reshef, MD MSc, Markus Y Mapara, MD PhD

Blood (2018) 132 (Supplement 1): 5713.

https://doi.org/10.1182/blood-2018-99-116538

Published: 2018

Journal Articles

The Inhibition of Gck Affect MAPK Cascade in Multiple Myeloma

Shirong Li, Jing Fu, PhD, Shixian Deng, Hsin S Wang, Xiaoming Xu, Markus Y Mapara, MD PhD, Donald W Landry, Suzanne Lentzsch, MD PhD

Blood (2018) 132 (Supplement 1): 3202.

https://doi.org/10.1182/blood-2018-99-117557

Published: 2018

Journal Articles

Gastrointestinal Toxicity of High-Dose Melphalan in Autologous Stem-Cell Transplantation: Identification of Risk Factors and a Benchmark for Experimental Therapies

Christian Gordillo, BS, Sapna Parmar, PharmD, Miranda Blanco, BS, Elsa Marie Delille, NP, Amer Assal, MD, Markus Y Mapara, MD PhD, Ran Reshef, MDMSc

Blood (2017) 130 (Supplement 1): 5464.

https://doi.org/10.1182/blood.V130.Suppl_1.5464.5464

Published: 2017

Journal Articles

An Open-Label Phase I/II Study of Carfilzomib, Bendamustine and Dexamethasone (CBD) in Newly Diagnosed Multiple Myeloma Patients

Siyang Leng, MD, Shahzad Raza, MD, Amer Assal, MD, Gregory Baliko, BS, Julia Gould, BA, Rachel K Shields, BA, Markus Y Mapara, MD PhD, Suzanne Lentzsch, MD PhD

Blood (2017) 130 (Supplement 1): 1863.

https://doi.org/10.1182/blood.V130.Suppl_1.1863.1863

Published: 2017

NARROW

Gck Inhibition Is a Novel Therapeutic Strategy for RAS Mutated Multiple Myeloma and Overcomes Resistance to IMiDs

Resolution of Serious Vaso-Occlusive Pain Crises and Reduction in Patient-Reported Pain Intensity: Results from the Ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy

Checkpoint Inhibitor PD-1H/VISTA Mediates MMP-13 Induced Osteoclast Activation and Multiple Myeloma Bone Disease

Glucagon-like Peptide-2 (GLP-2) Treatment Reduces Gvhd-Related Mortality in a Pre-Clinical Transplant Model Via Expansion of Macrophages with Tolerogenic Potential

Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells

Improvements in Health-Related Quality of Life for Patients Treated with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy

Gck Kinase Activity Is Critical for RAS Mutated Myeloma - a Potential Treatment Approach for Targeting Specific Mutations

Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy

Excellent Survival and Immune Reconstitution Following Matched/Mismatched Unrelated and Mismatched Related Transplantation in Adult Patients with Sickle Cell Disease: Updated Results from a Single Center Experience

Role of MMP-13 in Graft-Versus-Host Disease

Autologous Transplant Recipients Have a Healthier Gut Microbiota at Baseline and Faster Recovery from Microbiome Injury Compared to Allogeneic Transplant Recipients

Checkpoint Inhibitor PD-1H/VISTA Functions As MMP-13 Receptor on Osteoclasts and Mediates MMP-13 Induced Osteoclast Activation in Multiple Myeloma

Resolution of Sickle Cell Disease Manifestations in Patients Treated with Lentiglobin Gene Therapy: Updated Results from the Phase 1/2 Hgb-206 Group C Study

Combination Chemotherapy with Carfilzomib, Bendamustine and Dexamethasone Is Highly Active for Therapy of Newly Diagnosed Multiple Myeloma-Results of Single Center Phase I/II Study

Current Results of Lentiglobin Gene Therapy in Patients with Severe Sickle Cell Disease Treated Under a Refined Protocol in the Phase 1 Hgb-206 Study

Outcomes for Initial Patient Cohorts with up to 33 Months of Follow-up in the Hgb-206 Phase 1 Trial

Curative Allogeneic Stem Cell Transplantation Is Safe and Feasible in Adult Patients with Sickle Cell Disease Despite Lack of Matched Sibling Donor and Presence of Sickle Cell-Related Co-Morbidities

The Inhibition of Gck Affect MAPK Cascade in Multiple Myeloma

Gastrointestinal Toxicity of High-Dose Melphalan in Autologous Stem-Cell Transplantation: Identification of Risk Factors and a Benchmark for Experimental Therapies

An Open-Label Phase I/II Study of Carfilzomib, Bendamustine and Dexamethasone (CBD) in Newly Diagnosed Multiple Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only